Feb 28, 2007 by Brian LawlerWorrisome WatsonThe maker of generic drugs could have a challenging year ahead.
Feb 28, 2007 by Brian LawlerMylan Denied ... for NowThe generic-drug maker loses its court battle to overturn the patents on Pfizer's No. 2 drug.
Feb 27, 2007 by Brian LawlerMostly Good From BioMarinDrugmaker BioMarin updates investors on its drug pipeline and quarterly financial results.
Feb 27, 2007 by Brian LawlerGilead's Green-Lighted DrugFebruary was a busy month for drug developer Gilead Science's developmental pipeline.
Feb 27, 2007 by Brian LawlerThree Strikes for TelikThere's not much in the pipeline at this small biotech company.
Feb 27, 2007 by Brian LawlerPDL Keeps Us WaitingPDL BioPharma announces its year-end financial results.
Feb 27, 2007 by Brian LawlerFDA Keeps Novartis WaitingNovartis experiences a regulatory setback in the U.S. for one of its top drug candidates.
Feb 26, 2007 by Brian LawlerShire's Busy WeekShire announces year-end results, new regulatory approval, and another acquisition.
Feb 26, 2007 by Brian LawlerWaiting on AtheroGenicsThe results might be positive, but don't bet on it.
Feb 23, 2007 by Brian LawlerLack of Progress at PanacosWhat's next for bevirimat, its compound for HIV?
Feb 22, 2007 by Brian LawlerDueling Fools: Pfizer BearIt's been a blue chip for years, but that doesn't mean it will stay that way forever.
Feb 22, 2007 by Brian LawlerDueling Fools: Pfizer Bear RebuttalGeneric competition for Lipitor is just the beginning.
Feb 22, 2007 by Brian LawlerToo Much Aplomb From ElanElan releases its 2006 financial results, and its future is not as rosy as seems.
Feb 21, 2007 by Brian LawlerGilead Closes the GapThe FDA trims Gilead's review period for a top developmental compound.
Feb 20, 2007 by Brian LawlerSanofi Sweats the GenericDrugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
Feb 16, 2007 by Brian LawlerCephalon's Supercharged GrowthThe pharmaceutical announces Q4 results and updates 2007 guidance.
Feb 15, 2007 by Brian LawlerA Momenta's PauseThe pharmaceutical elaborates on plans for its generic version of blockbuster Lovenox.
